Liquidia price target raised to $42 from $38 at BofA
BofA analyst Jason Gerberry raised the firm’s price target on Liquidia (LQDA) to $42 from $38 and keeps a Neutral rating on the shares following a global litigation settlement with…
Fiscal Year: January - December
Liquidia Corporation (LQDA), listed on the NASDAQ, has a market capitalization of $3.05B. As of Oct 20, 2026, the stock is trading at $34.13 per share@else an unavailable price , offering investors a clear view of its current market value. Liquidia Corporation is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 23.09, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Liquidia Corporation also offers a dividend yield of N/A , making it an attractive option for income-focused investors who seek regular dividends.
DCF analysis data is not yet available for Liquidia Corporation (LQDA). A fair value is shown for companies with at least three years of reported free cash flow and a positive typical free cash flow margin. Banks, insurers and REITs need a different valuation model and are not covered yet.
The proprietary SS Score for Liquidia Corporation is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Liquidia Corporation, Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Liquidia Corporation is 20.27, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Liquidia Corporation (LQDA) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Liquidia Corporation (LQDA) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. It is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Liquidia Corporation (LQDA) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Liquidia Corporation. To access the full SS Score, consider upgrading your subscription.
Liquidia Corporation is a significant player in the industry sector, with a market capitalization of $3.05B and a competitive P/E ratio of 23.09. Investors should compare these metrics with industry peers to gauge whether Liquidia Corporation is outperforming or underperforming within its sector.
BofA analyst Jason Gerberry raised the firm’s price target on Liquidia (LQDA) to $42 from $38 and keeps a Neutral rating on the shares following a global litigation settlement with…
H.C. Wainwright raised the firm’s price target on Liquidia (LQDA) to $65 from $58 and keeps a Buy rating on the shares after the company announced a global settlement with…
Liquidia surges after reaching a $380.7 million settlement with United Therapeutics resolving patent disputes for its lung disease drug.
LifeSci Capital upgraded Liquidia (LQDA) to Outperform from Market Perform with a $59 price target. The company announced a settlement with United Therapeutics (UTHR) that resolves all six pending law...
LifeSci Capital analyst Gaurav Maini upgraded Liquidia (LQDA) to Outperform from Market Perform with a $59 price target
Needham lowered the firm’s price target on Liquidia (LQDA) to $58 from $72 and keeps a Buy rating on the shares. The firm is adjusting its model after the company…
Wells Fargo raised the firm’s price target on Liquidia (LQDA) to $33 from $30 and keeps an Equal Weight rating on the shares after the company and United Therapeutics (UTHR)…
As previously reported, BTIG upgraded Liquidia (LQDA) to Buy from Neutral with a $70 price target after the company announced it reached a global settlement with United Therapeutics (UTHR) to…
BTIG upgraded Liquidia (LQDA) to Buy from Neutral with a $70 price target
Liquidia ($LQDA) stock jumped about 47% in Wednesday’s pre-market trading after the biopharmaceutical company focused on respiratory and vascular diseases announced a $380.7 million settlement with Un...
The yield on the 10-year Treasury note slipped below 5.2% for the first time in nearly two weeks on Tuesday, and yet sentiment in equities remained cautious, with little support…
Liquidia (LQDA) and United Therapeutics (UTHR) reached a global settlement agreement that resolves all pending litigation between the companies. YUTREPIA, or treprostinil, inhalation powder will remai...
17:57 EDT Liquidia (LQDA) up 40% to $37.59 after settlement agreement with United Therapeutics (UTHR)
Liquidia (LQDA) announced that it has entered into a global settlement agreement with United Therapeutics (UTHR) that resolves all pending litigation between the companies. Importantly, YUTREPIA, or t...
MORRISVILLE, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challengi...
LOS ANGELES--(BUSINESS WIRE)---- $LQDA--LQDA Investors with $100,000 in Losses Have Opportunity to Join Liquidia Corporation Fraud Investigation with SBS Law.
A court finding that Yutrepia infringed two valid claims of United Therapeutics' '327 patent has put the drug's PH-ILD indication and broader availability at risk. SueWallSt notifies investors of a pe...
Liquidia shares plunged nearly 50% on Wednesday after a federal judge ruled that its lung drug infringes key patent held by rival United Therapeutics , dealing a major blow to the treatment's commer...
District Court ruled that two of the six claims asserted against Liquidia are valid and infringed Parties directed to submit form of judgment, specifying the proposed remedy, for the District Court's ...
Fast Track designation underscores the significant unmet need for patients with systemic sclerosis-associated Raynaud's phenomenon (SSc-RP), a debilitating manifestation affecting up to 90% of SSc pat...
MORRISVILLE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challeng...
MORRISVILLE, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that Michael Kaseta, Chief Operating Officer and Chief Financial Officer, and Jason Adair, Chi...
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.